David P. Ryan
Harvard University · 825 works · 34,665 citations · h-index 91
Top works
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
- Pancreatic Adenocarcinoma
- Colon Cancer
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
- Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors
- Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial
- Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
- Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients
- Carcinoma of the Anal Canal
- Rectal Cancer
- Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma